Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom.

ABSTRACT:

Aim

To examine trends of second-line glucose-lowering therapies among patients with type 2 diabetes (T2D) initiating first-line metformin in the United States and the United Kingdom, overall and by subgroups of cardiovascular disease (CVD) and calendar time.

Methods

Using the US Optum Clinformatics and the UK Clinical Practice Research Datalink, we identified adults with T2D who initiated first-line metformin or sulphonylurea monotherapy, separately, from 2013 to 2019. Within both cohorts, we identified patterns of second-line medications through June 2021. We stratified patterns by CVD and calendar time to investigate the impact of rapidly evolving treatment guidelines.

Results

We identified 148 511 and 169 316 patients initiating treatment with metformin monotherapy

SUBMITTER: Abrahami D 

PROVIDER: S-EPMC10527897 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature